(Q34581641)

English

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study (English)

1 reference

Europe PubMed Central

3 August 2017

0 references

multiple sclerosis

0 references

Hans-Peter Hartung

5

object named as

Hans-Peter Hartung

1 reference

Europe PubMed Central

3 August 2017

1

object named as

Ludwig Kappos

1 reference

Europe PubMed Central

3 August 2017

Frederik Barkhof

8

object named as

Frederik Barkhof

1 reference

Europe PubMed Central

3 August 2017

David H. Miller

6

object named as

David H Miller

1 reference

Europe PubMed Central

3 August 2017

3

object named as

Chris H Polman

1 reference

Europe PubMed Central

3 August 2017

author name string

Mark S Freedman

2

1 reference

Europe PubMed Central

3 August 2017

Gilles Edan

4

1 reference

Europe PubMed Central

3 August 2017

Xavier Montalbán

7

1 reference

Europe PubMed Central

3 August 2017

Ernst-Wilhelm Radü

9

1 reference

Europe PubMed Central

3 August 2017

Lars Bauer

10

1 reference

Europe PubMed Central

3 August 2017

Susanne Dahms

11

1 reference

Europe PubMed Central

3 August 2017

Vivian Lanius

12

1 reference

Europe PubMed Central

3 August 2017

Christoph Pohl

13

1 reference

Europe PubMed Central

3 August 2017

Rupert Sandbrink

14

1 reference

Europe PubMed Central

3 August 2017

BENEFIT Study Group

15

1 reference

Europe PubMed Central

3 August 2017

language of work or name

0 references

publication date

1 August 2007

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

370

1 reference

Europe PubMed Central

3 August 2017

389-397

1 reference

Europe PubMed Central

3 August 2017

9585

1 reference

Europe PubMed Central

3 August 2017

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961194-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961194-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961194-5

7 January 2021

based on heuristic

inferred from DOI database lookup

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961194-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961194-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961194-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Axonal transection in the lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961194-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961194-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961194-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of the functional assessment of multiple sclerosis quality of life instrument

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961194-5

7 January 2021

based on heuristic

inferred from DOI database lookup

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961194-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961194-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961194-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961194-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961194-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cortical motor reorganization after a single clinical attack of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961194-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of relapses on development of residual deficit in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961194-5

7 January 2021

based on heuristic

inferred from DOI database lookup

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961194-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961194-5

7 January 2021

based on heuristic

inferred from DOI database lookup

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961194-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961194-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(07)61194-5

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34581641&oldid=1772736075"